Drugs / SARS-CoV-2 plasma
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04411602 | Apr 2020 → Apr 2021 | COVID-19, severe acute respiratory syndrome | Henry Ford Health System | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04411602 ↗ |
| Modality | Protein / enzyme biologic | “The study drug is the investigational product, anti-SARS-CoV-2 convalescent plasma obtained from the American Red Cross or local plasma supply” NCT04411602 ↗ |